Eugen Leo

Head, Clinical Development at Isarna Therapeutics GmbH

Eugen Leo

Eugen Leo

Head, Clinical Development at Isarna Therapeutics GmbH

Overview
RelSci Relationships

136

Relationships
RelSci Relationships are individuals Eugen Leo likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former President & Chief Executive Officer at Isarna Therapeutics GmbH

Relationship likelihood: Strong

Head, Preclinical Research & Development at Isarna Therapeutics GmbH

Relationship likelihood: Strong

Co-Founder & Chief Executive Officer at Oxford BioTherapeutics Ltd.

Relationship likelihood: Strong

General Manager at Isarna Therapeutics GmbH

Relationship likelihood: Strong

Chief Medical Officer at Oxford BioTherapeutics Ltd.

Relationship likelihood: Strong

Section Head of Endocrinology-5th Medical Department, University Medical Center Mannheim at University of Heidelberg, Germany

Relationship likelihood: Strong

Chairman-Ophthalmology Department at University of Heidelberg, Germany

Relationship likelihood: Strong

Director-Physiology & Pathophysiology at University of Heidelberg, Germany

Relationship likelihood: Strong

General Partner, Life Sciences at Wellington Partners GmbH

Relationship likelihood: Strong

Professor at University of Heidelberg, Germany

Relationship likelihood: Strong

Paths to Eugen Leo
Potential Connections via
Relationship Science
You
Eugen Leo
Head, Clinical Development at Isarna Therapeutics GmbH
Career History
Chief Medical Officer
2017 - Current

Rigontec GmbH provides RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The firm develops a compound stimulating the immune receptor retinoic acid-inducible gene. The company was founded by Annegret de Baey-Diepolder, Gunther Hartmann, Anna Schwickart, Marcel Renn, Christine Schuberth-Wagner and Veit Hornung in 2014 and is headquartered in Munich, Germany.

Head, Clinical Development
2012 - Current

Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany.

Professor
Current

Ruprecht-Karls-Universität Heidelberg

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Eugen Leo. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Eugen Leo's profile does not indicate a business or promotional relationship of any kind between RelSci and Eugen Leo.